Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Myocarditis following COVID-19 mRNA vaccination

Saif Abu Mouch a,b,⇑, Ariel Roguin b,c, Elias Hellou b,c, Amorina Ishai b,d, Uri Shoshan a,b, Lamis Mahamid b,e, Marwan Zoabi a,b, Marina Aisman a, Nimrod Goldschmidt b, Noa Berar Yanay b,f

a Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel
b Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
c Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel
d Department of Imaging, Hillel Yaffe Medical Center, Hadera, Israel
e Infectious Disease Unit, Hillel Yaffe Medical Center, Hadera, Israel
f Department of Nephrology, Hillel Yaffe Medical Center, Hadera, Israel

1. Introduction

1.1. Background

On December 2020 the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine (BNT162b2) for prevention of COVID-19 disease. The vaccine's EUA relied on data which were obtained from several clinical trials [1,2]. The results of these trials revealed that the vaccine's efficacy is 95% and its safety profile is good and similar to that of other vaccines [1–3]. Systemic reactions to the vaccine, which were usually mild and transient, were reported more commonly among the younger population and more often after the second dose [1,2].

In Israel, the nationwide rollout of the 2-dose BNT162b2 vaccination program started in December 2020. More than 4 million people have received two doses of the vaccine, by the time of writing. These include persons 16 years old and older. In this report, we inform on the unforeseen occurrence of myocarditis in five male persons shortly after they received two doses of the BNT162b2 vaccine and in one male person 16 days after he received the first dose of the BNT162b2 vaccine. We suspect that these adverse events were related to the vaccine.

1.2. Patients and Clinical, laboratory and imaging Assessments

In a three-week interval (January 30th through February 20th 2021, six men were hospitalized with suspected myocarditis, all shortly after the vaccination. The COVID-19 status of the six...
patients was assessed by reverse transcription-polymerase chain reaction (RT-PCR) of nasopharyngeal swabs (TaqPath™ COVID-19 Combo Kit, Thermo Fisher Scientific) and serological determination of the antibody levels against viral nucleocapsid (anti N Ab) (Anti-Nucleocapsid antibodies- Elecsys® N Anti-SARS-CoV-2, Cobas®, Roche Diagnostics) and spike proteins (anti S Ab) (Anti-Spike antibodies, LIAISON® SARS-CoV-2 S1/S2 IgG DiaSorin).

The laboratory tests also included a routine complete blood count, complete metabolic panel, troponin, C-reactive protein, PCR testing and serological determination of antibodies against common infectious pathogens related to myocarditis (for details see supplementary).

1.3. Cardiac imaging

When a coronary event was suspected, a computerized tomography (CT) coronary angiogram or a diagnostic coronary angiogram was done. Transthoracic echocardiography and cardiac magnetic resonance imaging (CMR) were done in all patients.

Routine ECG-gated CMR was performed on a 1.5 Tesla magnet (Philips Ingenia 1.5 T MRI system) equipped with phased array body coils for signal reception using commercially available cardiac software (for CMR protocol see supplementary).

CMR analyses were performed offline using Philips Intellispace Portal by an experienced radiologist.

The CMR diagnosis was made in accordance with prior published recommendations in the presence of typical non-ischemic myocardial injury [4].

2. Results

Six patients (16–45 years; median 22 years) were evaluated because of chest pain/discomfort (Table 1). Five patients presented 24–72 h after receiving the second dose of the vaccine and one patient presented 16 days after receiving the first dose of the vaccine. All patients had an abnormal electrocardiogram (Fig. 1) and elevated serum C-reactive protein levels (56–347 mg/L; normal level < 5.0 mg/L). Five patients had elevated serum troponin T levels (peak levels 392–1062 ng/L; normal level < 13 ng/L) and one patient had an elevated high-sensitivity cardiac troponin-I level (14350 ng/L; normal level < 34 ng/L). The supplementary material details the laboratory results of each patient.

The echocardiographic examination was normal in four patients, and revealed a borderline left ventricular ejection fraction in two patients. The CMR revealed findings which were compatible with myocarditis (myocardial edema and late gadolinium enhancement) in all patients (Fig. 2, and supplementary material).

No significant narrowing of the coronary arteries was noted in one patient who had a cardiac CT and another patient who had coronary angiography.

All six patients presented in less than a month period. We investigated the background rate of myocarditis during winter months (December through March) in our hospital in the past 5 years, and found a mean of 1.17 cases of myocarditis per month (range 0–3 cases per month).

The disease course was mild in all patients. They were treated with a nonsteroidal anti-inflammatory drug and colchicine and were discharged 4–8 days after admission for outpatient follow-
**Clinical and laboratory summary of the study population.**

| No. | Age/sex/ Time of presentation | ECG | Peak CRP* Peak Troponin-T* Serology**RT-PCR *** | COVID-19 status | TTE | Coronary imaging | Cardiac MRI |
|-----|-----------------------------|-----|---------------------------------------|-----------------|-----|-----------------|------------|
| Case 1 | 24 y, male, 72 h after receiving the 2nd dose of the vaccine | Diffuse ST elevation Inverted T lead III | CRP - 58.1 mg/L; Troponin T - 589 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | Normal study | NA | T2 sequence showed mild myocardial edema of the basal septum and inferolateral wall. |
| Case 2 | 20 y, male, 24 h after 2nd vaccine | Sinus tachycardia ST elevation V2-6 | 100.0 mg/L Troponin T - 1062 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | Normal study | CT Angiography: NCA | T2 sequence showed mild myocardial edema with LGE in the subepicardial region of the basal and middle anterolateral and inferolateral walls |
| Case 3 | 29 y, male, 48 h after receiving the 2nd dose of the vaccine | Diffuse PR depression Diffuse ST elevation | CRP - 85.0 mg/L; Troponin T - 876 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | Normal study | NA | T2 sequences showed mild diffuse myocardial edema and LGE of the basal, inferolateral, anterolateral and anteroseptal walls |
| Case 4 | 45 y, male, 16 days after receiving the 1st dose of the vaccine | ST elevation: I, aVL, V3-5 inverted T, ST depression: III, aVF | CRP - 56.2 mg/L; Troponin T - 392 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | LVEF-50-55% LGE of the affected walls | LVEF 50-55% LGE sequence showed subepicardial edema of the middle anterolateral, inferolateral and of the apical anterior walls with LGE of the affected walls |
| Case 5 | 16 y, male, 24 h after receiving the 2nd dose of the vaccine | ST elevation V2-4 | CRP - 1.5 mg/L; Troponin T - 14350 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | Normal study | NA | Normal LV size LVEF 59% LGE sequence show midmyocardial and subepicardial edema of the basal inferolateral and middle anterolateral segments. LGE present in the same segments |
| Case 6 | 17 y, male, 72 h after receiving the 2nd dose of the vaccine | ST elevation I II aVL, V2-6s, QRS TII | CRP - 54.7 mg/L; Troponin T - 1130 ng/L; Serology - negative; RT-PCR - negative | RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative) | Normal study | NA | T2 sequence showed subepicardial edema of the basal inferolateral, middle inferolateral and infero-septal and apical lateral, anterior and inferior walls. LGE present in the same segments and mid-myocardial enhancement of the middle inferolateral and anterolateral and apical anterior and lateral walls. Findings consistent with myo-pericarditis. |

**ECG** - electrocardiography; **EF** - Ejection Fraction; **TTE** - transthoracic echocardiography; **NA** - not assessed; **NCA** - normal coronary arteries; **LV** - Left Ventricle; **LGE** - late gadolinium enhancement.  
* Serum C-reactive protein (CRP) level (normal range (0.0–5.0 mg/L); serum troponin T level (normal range 0.0–13.0 ng/L; Above 50 – positive).  
** Serology: Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis B virus (HBV), Coxsackie viruses, parvovirus B19, Coxiella burnetii, Mycoplasma pneumoniae.  
*** RT-PCR: adenovirus, parainfluenza, respiratory syncytial virus (RSV), influenza A virus, influenza B virus, enterovirus, human metapneumovirus, Bordetella pertussis, Bordetella para-pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae.  

up (see supplementary material for detailed case report of each patient).  

### Discussion

We identified six cases of clinically suspected myocarditis in otherwise healthy male individuals shortly after they received the BNT162b2 mRNA COVID-19 vaccine. Five patients presented shortly after the second vaccine dose and one patient presented 16 days after receiving his first vaccine dose. We included this patient because of identical clinical investigation results and clinical course. We considered and assessed a wide range of differential diagnoses for these cases.

#### 3.1. COVID-19 associated myocarditis

Myocarditis is reported to be one of the manifestations of COVID-19 infection. The proposed pathophysiology involves direct damage by (a) invasion of the virus into cardiomyocytes, (b) the host immune response of cytotoxic T lymphocytes, and (c) the presence of over-inflammation and the cytokine storm [4,5]. Although protection from COVID-19 infection takes a few days to develop after receiving the second dose of the vaccine, COVID-19 infection can still occur in this early period. We ruled out COVID-19 infection in our patients. All patients were COVID-19 RT-PCR negative and nonreactive for nucleocapsid protein (anti N Ab Negative). All patients responded to the vaccine, as evidenced for being found positive for antibodies against the spike protein (anti S Ab positive).

#### 3.2. Infectious autoimmune and toxic/drug exposure

We performed antibody and PCR testing for common pathogens associated with myocarditis and pericarditis and found no indication of any concomitant infection. None of our patients had any clinical sign or laboratory finding compatible with autoimmune disease. None of the patients had a history of an exposure to new drugs or toxins prior to onset of their symptoms.

#### 3.3. Myocarditis as an adverse reaction to the COVID-19 vaccine

In general, myocarditis, is considered an uncommon adverse event following immunization [6–8]. An exception to this generalization is myocarditis following smallpox vaccination in adults with a reported incidence of 1:10,000 [7,9–12]. In a prospective safety surveillance study of perimyocarditis following smallpox vaccine, the authors report that most of the identified cases of perimyocarditis were subclinical and were identified through routine
pre and post vaccination troponin level measurements [13]. This finding raises concern that we identified only the “tip of the iceberg” i.e. symptomatic cases and other asymptomatic cases may had not been detected.

An important consideration is a comparison of number of cases of suspected myocarditis post vaccination to the background rate of myocarditis. Our hospital serves a population of approximately 500,000 people. The mean number of myocarditis cases in winter months (December through March) for the past 5 years was 1.17 cases per month. Our six patients presented in less than a month period, indicating a higher rate.

The development and approval via Emergency Use Authorization of vaccines for the prevention of infection with COVID-19 is a huge step forward to control the disease and decrease morbidity and mortality.

It is possible that uncommon adverse reactions to the COVID-19 vaccine may have not been captured during the clinical trials due to low rate of myocarditis and the relatively limited size of the population that received the vaccine before its authorization. In Israel, nationwide vaccination rollout started at the end of December 2020. Near 4 million people had already received two doses of the BNT162b2 vaccine at the time of writing. The vaccination of a large population in a short period may allow detection of less common vaccination-related events.

Immunization against COVID-19 and other viral pathogens using mRNA-based vaccines is a new and promising technology [13,14]. In the clinical trials, systemic adverse reactions after the second dose were reported more frequently mainly in the younger population with a median onset time of 1–2 days [1,2]. This time pattern fits five of our six cases. Also, the relatively young age profile for the systemic drug reactions described for the vaccine fits all our patients.

The course of the disease was mild in our patients. However, myocarditis may have a more severe clinical presentation, may impose limitations on physical activity and may require long-term medical treatment, and follow-up [15,16].

4. Conclusion

Our report on the occurrence of myocarditis after BNT162b2 mRNA COVID-19 vaccination in six male patients may be possibly considered to be an adverse reaction following immunization. Accordingly, it is important to collect more data on this entity as the vaccine becomes more widely distributed, and more data on the vaccine’s efficacy and safety is obtained. It is important to interpret our data with caution because public acceptance of COVID-19 vaccines is much needed. The individual and public benefit from COVID-19 vaccination outweighs these rare findings described herein.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2021.05.087.

References

[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603–15.
[2] Walsh EE, French Jr RW, Falsy AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020;383:2439–50.
[3] Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 2020;69:1922–4.
[4] Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018;72:3158–76.
[5] Siripanthong B, Nazarian S, Muser D, Reis R, Santangeli P, Khanji MY, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 2020;17:1463–71.
[6] Abbasi J. Researchers Investigate What COVID-19 Does to the Heart. JAMA 2021:325:308–11.
[7] Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vennalis MN. Smallpox vaccination and myocarditis/myopericarditis: a clinical review. J Am Coll Cardiol 2004;44:201–5.
[8] Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell CL, et al. Inocence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004;44:201–5.
[9] Su JR, McNeil MM, Welsh KJ, Markquez PL, Ng C, Yan M, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine 2021;39:839–45.
[10] Mei R, Raschi E, Forceti G, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after immunization: A comprehensive update. Expert Rev Cardiovasc Ther 2019;17:1463–71.
[11] Engel RJ, Nelson MR, Collins Jr LC, Spooner C, Hemann BA, Gibbs ET, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS ONE 2015;10:e0118283.
[12] Kuntz J, Crane B, Weismann S, Naleway AL. Vaccine Safety Datalink Investigator T. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine 2018;36:1524–7.
[13] Faix DJ, Gordon DM, Perry LN, Raymond-Loher I, Tati N, Lin G, et al. Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine 2020;38:7323–30.
[14] Chimalmanki R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells 2021;10.
[15] Pardini N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccineimmunology. Nat Rev Drug Discov 2018;17:261–79.
[16] Cafiero ALP, Adler Y, Agostini C, Allanoire Y, Anastasakis A, Arad M, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J 2017;38:2649–62.